SS-31 (Elamipretide)

• Mitochondrial rejuvenationrecommended

  The guide's standard cycle; run 2-3 times a year.

• 40 mg once daily (range 20-40 mg) for 20-30 days; 25 days used for 1,000 mg total

Route: Subcutaneous: abdominal fat pad or outer thigh.

Timing: First thing in the morning, or 30-45 minutes before a workout.

• 50 mg vial + 1.0 mL bacteriostatic water or saline = 50 mg/mL
• 40 mg = 0.8 mL = 80 units
• 20 vials for 25 days; 1.25 doses per vial, leftovers pooled (4 leftovers = 1 dose)

Refrigerate (36-46 °F). Use within 7 days. Swirl gently.

12-16 weeks off; typically 2-3 cycles a year.

Why:

• Diminishing returns once cardiolipin is stabilised.
• Benefits are described as persisting after the cycle.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.
• Applies to MOTS-c and NAD+ as well.

What sources report this compound changes, or say to check. A record of the evidence, not targets or advice.

• 6-minute walk distanceReported changeHuman trial

  Rose about 96 m at 36 weeks in the open-label part of TAZPOWER in Barth syndrome (p = 0.024); the randomized part missed its primary endpoints.

  Stealth BioTherapeutics: positive results for elamipretide in Barth syndrome open-label extension (TAZPOWER)
• Knee extensor muscle strengthReported changeDrug label

  Improvement in knee extensor strength was the basis for FDA accelerated approval in Barth syndrome (patients 30 kg or more); continued approval depends on a confirmatory trial.

  FORZINITY (elamipretide) prescribing information, DailyMed